Capsinoid Treatment for Benign Prostatic Hypertrophy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for bladder outlet obstruction (BOO) due to benign prostatic hypertrophy (BPH) are either ineffective or come with adverse side effects, necessitating a safe and effective method to alleviate urine retention symptoms.

Innovation Solution

Administering a therapeutic dose of capsaicin or a capsaicin agonist/analogue, equivalent to 20,000-200,000 Scoville Heat Units (SHU), orally to reduce bladder outlet obstruction and frequency of self-catheterization in patients with BPH.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatments for BPH are administered, then bladder outlet obstruction is addressed, but adverse side effects occur

Engineering Contradiction:

Improveeffectiveness of BPH treatmentVSAvoidadverse side effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the chemical parameter by using capsinoids (capsaicin analogs) instead of conventional BPH medications. This substitution maintains therapeutic effectiveness while eliminating the adverse side effects associated with traditional treatments, as capsinoids work through a different mechanism (TRPV1 receptor modulation) that does not produce the same harmful effects.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent employs a natural-derived compound (capsinoid) that can be administered orally and acts temporarily to reduce prostate size and improve urinary flow. The capsinoid formulation provides effective treatment without the long-term cumulative side effects of conventional medications, allowing for periodic administration.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

2Ease of operation

If self-catheterization is used to overcome BOO symptoms, then urine retention is relieved, but treatment complexity and patient burden increase

Engineering Contradiction:

Improvemanagement of urine retentionVSAvoidself-catheterization procedure

Core Design Contradiction:

Ease of operationVSDevice complexity

Solution Approach 1:

The capsinoid treatment enables the patient's body to self-regulate urinary flow by reducing prostate size and relieving bladder outlet obstruction. Instead of requiring manual catheterization, the medication allows the urinary system to function naturally, eliminating the need for invasive self-catheterization procedures.

Inventive Principle:

Principle #25Self-service

3Reliability

If conventional medications are used to treat BPH, then symptoms are managed, but treatment effectiveness is limited

Engineering Contradiction:

Improvesymptom managementVSAvoidurine flow improvement

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent changes the therapeutic parameter by using capsinoids that directly reduce prostate tissue volume and improve urinary flow rate. Unlike conventional medications that primarily manage symptoms, capsinoids actively shrink the prostate and enhance urine flow productivity, providing more effective treatment for moderate to severe BPH cases.

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS12274680B2Treatment of benign prostatic hypertrophy with capsinoids

Publication Date: 2025.04.15 POPULATION COUNCIL INC

AI summary

A method for reducing bladder outlet obstruction and/or self-catheterization frequency of a male patient with bladder outlet obstruction (BOO) due to benign prostatic hypertrophy (BPH) is disclosed. The method comprises orally administering to a male patient suffering from BOO due to BPH an effective amount of an active ingredient selected from a capsinoid mixture, enabling the patient suffering from BOO due to BPH to reduce BOO and/or the self-catheterization frequency.